[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
October 26, 2018
VANCOUVER, British Columbia — Vancouver based microbiome startup Derm-Biome Pharmaceuticals Inc. is excited to announce that it has contracted the Centre for Drug Research and Development (CDRD) to commence testing its patented compounds on various pathogens. Lead compound DB-207 shows significant potential in patients with acne, rosacea, minor skin bacterial infections, conjunctivitis, and neoplastic skin disease, with the beneficial side effect of improving the appearance of surrounding skin. Award winning researcher Dr. Poul Sorensen and his lab at the BC Cancer Research Centre will soon begin testing DB-207 for effects on inflammation and skin cancer. The initial focus for the company will be in the areas of cosmetics (anti-aging products) as well as inflammatory and neoplastic skin disease, both offering huge market opportunities.
About Derm-Biome Pharmaceuticals, Inc
Derm-Biome Pharmaceuticals Inc. is a start-up life science company with issued patents covering over forty optimized natural compounds venturing into the new and exciting field of the skin microbiome. The company is excited that its compounds have the ability to balance and add diversity to our own unique bacterial communities, where a stable environment can positively affect our skin health, improve appearance, and ward off disease, including skin cancer. Moreover, these compounds have direct effects on cell growth and survival, which are currently under investigation by the company.
Contacts
Derm-Biome Pharmaceuticals, Inc.
Investor Inquiries:
Gord Eberwein
geberwein@derm-biome.com[/vc_column_text][vc_separator type=”normal” color=”#cccccc” thickness=”1″ up=”50″ down=”50″][/vc_column][/vc_row]